# TVB 2640 for Resectable Colon Cancer Other Resectable Cancers; a Window Trial.

> **NCT02980029** · PHASE1 · TERMINATED · sponsor: **Mark Evers** · enrollment: 23 (actual)

## Conditions studied

- Colon Cancer

## Interventions

- **DRUG:** TVB-2640
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02980029
- **Lead sponsor:** Mark Evers
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-10-06
- **Primary completion:** 2023-10-22
- **Final completion:** 2023-10-22
- **Target enrollment:** 23 (ACTUAL)
- **Why stopped:** Study was terminated by the PRMC for low accrual
- **Last updated:** 2024-10-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02980029

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02980029, "TVB 2640 for Resectable Colon Cancer Other Resectable Cancers; a Window Trial.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02980029. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*